VivoSeq
Neurology

Parkinsonism

17

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Parkinsonism is an emerging landscape with 17 programs across 7 companies. The most active players are Merck & Co., Merz Pharmaceuticals GmbH, Validus Pharmaceuticals. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

80/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1M

Merz Pharmaceuticals GmbH

1 program

Phase 1V

Validus Pharmaceuticals

1 program

Phase 2Lundbeck logo

Lundbeck

1 program

Phase 2Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

18 of 20 classified programs — the dominant modality here.

10%ALL OTHERSCell therapy210%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Withdrawn2 · 11%
Unknown status2 · 11%
Not yet recruiting2 · 11%
Terminated1 · 5%

Clinical Trials

Trial Activity

19 trials

Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism
Not yet recruiting·BBiocells Medical·Phase 2·NCT07471230·120 enrolled
Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
Not yet recruiting·—·Phase 1/2·NCT06858254·60 enrolled
Oxyhydrogen Nanobubble Infusion as a Complementary Therapy in Patients With Parkinsonism
Completed·Ddr. Siti Nurlaela, SpN·Phase 2/3·NCT07466381·35 enrolled
Novel Neuroimage Study in Tauopathies With Parkinsonism
Completed·—·Phase 2·NCT03386669·44 enrolled
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 1·NCT02214862·40 enrolled
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
Completed·National Institute on Aging (NIA)·Phase 4·NCT00043849·60 enrolled
The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography
Completed·—·Phase 2·NCT01824056·120 enrolled
Role of Pentoxifylline and Celecoxib in Parkinsonism
Completed·—·Phase 2·NCT05962957·80 enrolled
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
Completed·Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan·Phase 4·NCT00331825·70 enrolled
Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism
Completed·—·Phase 2·NCT02059733·72 enrolled
18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism
Completed·—·Phase 2·NCT02195154·13 enrolled
To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02265484·50 enrolled
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Completed·—·Phase 2·NCT01653132·10 enrolled
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00845000·12 enrolled
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Terminated·NNorthwestern University·N/A·NCT00745030·3 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)